Inhaltsbereich
| 13 Einträge |
Seite 1 / 1
 Druckansicht
|
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. |
| De Santis M, Bachner M, Cerveny M, Kametriser G, Steininger T, Königsberg R, Schratter-Sehn A, Sedlmayer F, Dittrich C |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Jun 16. pii: mdu209. doi: 10.1093/annonc/mdu209 |
| PMID: 24936582 |
| The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. |
| Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M |
| British journal of cancer. 2013 Oct 24. pii: bjc2013671. doi: 10.1038/bjc.2013.671. pmc: PMC3859949 |
| PMID: 24157828 |
| EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. |
| Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct 3. pii: mds334. doi: 10.1093/annonc/mds334. pmc: PMC3574544 |
| PMID: 23035151 |
| Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. |
| Kroiss R, Winkler V, Kalteis K, Bikas D, Rudas M, Tea M, Fuerhauser C, Muhr D, Cerny H, Glueck S, Petru E, Concin H, Kubista E, Oefner P, Wagner T |
| Journal of cancer research and clinical oncology. 2008 Apr 8. doi: 10.1007/s00432-008-0383-5 |
| PMID: 18392852 |
| Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. |
| De Santis M, Bachner M, Cerveny M, Kametriser G, Steininger T, Königsberg R, Schratter-Sehn A, Sedlmayer F, Dittrich C |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)35099-9. doi: 10.1093/annonc/mdu209 |
| PMID: 32018884 |
| 2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. |
| Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)39045-3. doi: 10.1093/annonc/mdr052 |
| PMID: 32018385 |
| 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. |
| Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Apr 2. pii: S0923-7534(19)39045-3. doi: 10.1093/annonc/mdr052 |
| PMID: 21460378 |
| Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. |
| Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R |
| The New England journal of medicine. doi: 10.1056/NEJMoa2104162 |
| PMID: 34320285 |
| MSX2 safeguards syncytiotrophoblast fate of human trophoblast stem cells. |
| Hornbachner R, Lackner A, Papuchova H, Haider S, Knöfler M, Mechtler K, Latos PA |
| Proceedings of the National Academy of Sciences of the United States of America. pii: 2105130118. doi: 10.1073/pnas.2105130118 |
| PMID: 34507999 |
| Perceptions of Practicing Physicians and Members of the Public on the Attributes of a "Good Doctor". |
| Dopelt K, Bachner YG, Urkin J, Yahav Z, Davidovitch N, Barach P |
| Healthcare (Basel, Switzerland). 2021 Dec 31. pii: healthcare10010073. doi: 10.3390/healthcare10010073 |
| PMID: 35052237 |
| Meteorological factors and non-pharmaceutical interventions explain local differences in the spread of SARS-CoV-2 in Austria. |
| Ledebur K, Kaleta M, Chen J, Lindner SD, Matzhold C, Weidle F, Wittmann C, Habimana K, Kerschbaumer L, Stumpfl S, Heiler G, Bicher M, Popper N, Bachner F, Klimek P |
| PLoS computational biology. 2022 Apr 4. doi: 10.1371/journal.pcbi.1009973. pii: PCOMPBIOL-D-21-01637 |
| PMID: 35377873 |
| Comorbidities and COVID-19 hospitalization, ICU admission and hospital mortality in Austria : A retrospective cohort study. |
| Rainer L, Bachner F, Eglau K, Ostermann H, Siebert U, Zuba M |
| Wiener klinische Wochenschrift. 2022 May 24. doi: 10.1007/s00508-022-02036-9. pii: 10.1007/s00508-022-02036-9 |
| PMID: 35608673 |
| 13 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
